enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · USD

$1.62

+0.17 (+11.7%)· Recorded snapshot

Market cap	108.6M
Net income (ttm)	-130.4M
EPS (ttm)	-$2.02
Shares out	67M
Volume	937,137.123
Beta	-0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -130.4M
EPS (ttm): -$2.02
Market cap: 108.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-60.5

P25 n/aP50 n/aP75 n/a

ROIC-34.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ENGN indicators

Market & fundamental data

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001980845
Company name	enGene Therapeutics Inc.
Country	Canada
Country code	US
CUSIP number	29286X101
Earnings date	2026-12-21
Earnings time	amc
Employees	82
Employees change	25
Employees growth	43.86%
Enterprise value	$-124.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-07-31
First seen	2026-05-09
Fiscal year end	October
Founded	1999
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	CA29286X1015
Last 10-K release date	2025-12-22
Last earnings date	2026-09-08
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$108.6M
Market cap category	Micro-Cap
Next earnings date	2026-12-21
Options	Yes
Price	$1.62
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-03
Symbol	ENGN
Website	https://www.engene.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-124.72%
FCF / EV yield	83.54%
FCF yield	-95.79%
P/B ratio	0.47x
Price / tangible book value	0.47x
Sector forward P/E	23.49x
Sector P/E	49.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.6M
ROA	-31.99%
ROCE	-52.33%
ROE	-60.5%
ROIC	-34.46%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-688,000
Depreciation and amortization	$718,000
EBIT	$-136.6M
EBITDA	$-135.9M
EPS	$-2.02
FCF per share	$-1.55
Financing cash flow	$143.7M
Free cash flow	$-104M
Free cash flow minus SBC	$-121.4M
Income taxes	$-497,000
Investing cash flow	$-32M
Net borrowing	$1.9M
Net cash flow	$8.4M
Net income	$-130.4M
Operating cash flow minus SBC	$-120.7M
Operating income	$-136.6M
Stock-based compensation	$17.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$3.44
Debt / equity	0.14
Interest coverage	-44.51
Long-term assets	$10.4M
Long-term liabilities	$30.8M
Net cash (debt)	$233M
Net cash / market cap	214.66%
Net cash growth	36.66%
Net debt / equity	-1.01
Piotroski F-Score	1
Property, plant and equipment	$9M
Shareholders' equity	$230.3M
Tangible book value	$230.3M
Tangible book value per share	$3.44
Total assets	$288.3M
Total cash	$266.3M
Total debt	$33.3M
Total liabilities	$58M
WACC	3.76%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$277.9M
Current liabilities	$27.2M
Current ratio	10.21
Net working capital	$-13.2M
Quick ratio	9.89
Working capital	$250.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-30.65%
Dividend yield	0%
Shareholder yield	-30.65%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.74
1D price change	11.72%
1M price change	-16.49%
1M total return	-16.49%
1W price change	4.52%
1W total return	4.52%
1Y price change	-77.53%
1Y return CAGR	-77.55%
1Y total return	-77.53%
20-day SMA	$1.62
200-day SMA	$4.29
3M price change	-9.5%
3M total return	-9.5%
3Y price change	-91.47%
3Y return CAGR	-55.98%
3Y total return	-91.47%
50-day SMA	$1.79
50-day SMA vs 200-day SMA	50under200
52-week high	$12.25
52-week high date	2026-01-23
52-week low	$1.40
52-week low date	2026-05-12
6M price change	-77.66%
6M total return	-77.66%
After-hours change	-2.46%
After-hours close	$1.62
After-hours price	$1.58
All-time high	$47.17
All-time high date	2023-10-26
All-time low	$1.40
All-time low date	2026-05-12
Average true range (ATR)	$0.09
Average volume	845.9K
Beta (1Y)	1.29
Beta (2Y)	0.44
Beta (5Y)	-0.28
Change from 52-week high	-86.78%
Change from 52-week low	15.71%
Change from all-time high	-96.57%
Change from all-time low	15.71%
Change from open	10.2%
Day's gap	1.38%
Dollar volume	$1.5M
High price	$1.63
Low price	$1.45
Monthly RSI	36.14
Open price	$1.47
Position in 52-week range	94.44%
Premarket change	-1.23%
Premarket close	$1.62
Premarket price	$1.60
Previous close	$1.45
Price vs 150-day SMA	-40.9%
Price vs 20-day SMA	0.06%
Price vs 200-day SMA	-62.25%
Price vs 50-day SMA	-9.4%
Relative volume	1.11
RSI	47.05
Sharpe ratio	-0.31
Sharpe ratio (3Y)	-0.12
Sortino ratio	-0.34
Sortino ratio (3Y)	-0.14
Volume	937.1K
Weekly RSI	33.42
YTD price change	-82.06%
YTD total return	-82.06%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	33M
Float percentage	49.29%
Shares change (QoQ)	0.01%
Shares change (YoY)	30.65%
Shares held by insiders	0.25%
Shares held by institutions	32.83%
Shares outstanding	67M
Short % of float	4.55%
Short % of shares	2.24%
Short ratio	1.9 days

Deeper analysis on ENGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ENGN report

Is a complete ENGN research report available?

No complete published report is available for enGene Therapeutics Inc. (ENGN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

enGene Therapeutics Inc. (ENGN)

Price

Financial snapshot

Fair-value bridge

Latest news · ENGN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ENGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ENGN

Frequently asked questions